Home  |   Archive  |   Online Submission  |   News & Events  |   Subscribe  |   APFA  |   Society  |   Contact Us  |   中文版
Search   
 
Journal

Ahead of print
Authors' Accepted
    Manuscripts
new!
Current Issue
Archive
Acknowledgments
Special Issues
Browse by Category

Manuscript Submission

Online Submission
Online Review
Instruction for Authors
Instruction for Reviewers
English Corner new!

About AJA

About AJA
Editorial Board
Contact Us
News

Resources & Services

Advertisement
Subscription
Email alert
Proceedings
Reprints

Download area

Copyright licence
EndNote style file
Manuscript word template
Guidance for AJA figures
    preparation (in English)

Guidance for AJA figures
    preparation (in Chinese)

Proof-reading for the
    authors

AJA Club (in English)
AJA Club (in Chinese)

 
中文摘要

《亚洲男性学杂志》 2014; 16 (3): 401-406

【特刊综述】聚ADP核糖聚合酶(PARP)抑制剂:前列腺癌治疗的一种演化模式

最近的I期研究报道了聚ADP核糖聚合酶(PARP)抑制剂在散发型和BRCA基因突变型前列腺癌中的单剂量活性。通过对临床前模型的研究,研究者们认为前列腺癌中最常见的两个基因改变——ETS基因重组和PTEN基因丢失,与前列腺癌对PARP抑制剂敏感性的增强有关。新的证据显示PARP1在介导雄激素受体转录活性和ETS基因重组中发挥重要作用。本文对推动以PARP抑制剂为基础的治疗作为转移性前列腺癌治疗新模式的临床前研究和早期临床试验进行了综述。

关键词:聚ADP核糖聚合酶(PARP)抑制剂,前列腺癌

 
Asian Journal of Andrology CN 31-1795/R ISSN 1008-682X  Copyright © 2023  Shanghai Materia Medica, Chinese Academy of Sciences.  All rights reserved.